Different effect of two immunomodulating agents cyclosporin A and ciamexon on the insulin metabolism of cultured mouse islets.
Diabetes Res
; 4(3): 121-3, 1987 Mar.
Article
en En
| MEDLINE
| ID: mdl-3038453
ABSTRACT
Ciamexon is a new immunomodulating agent with promising effects in treatment of newly-diagnosed insulin dependent diabetic patients. Ciamexon seems to have fewer adverse toxic properties than Cyclosporin A. Therefore, the effects of both substances on islet cell function were studied. Collagenase-isolated mouse islets were cultured free-floating for 3 or 7 days in medium RPMI 1640 plus 10% fetal calf serum in the presence of Cyclosporin A or Ciamexon (0.1 microgram/ml, 1 microgram/ml). Culture of the islets in the presence of 0.1 microgram/ml Ciamexon neither reduced the number of viable islets nor impaired insulin secretion as was found in Cyclosporin A. These results should be taken into account when treating early Type 1 diabetes or when transplanting islet cells.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Aziridinas
/
Azirinas
/
Adyuvantes Inmunológicos
/
Islotes Pancreáticos
/
Ciclosporinas
/
Insulina
Límite:
Animals
Idioma:
En
Revista:
Diabetes Res
Asunto de la revista:
ENDOCRINOLOGIA
Año:
1987
Tipo del documento:
Article